Next Article in Journal
Chromosome Synapsis and Recombination in Male-Sterile and Female-Fertile Interspecies Hybrids of the Dwarf Hamsters (Phodopus, Cricetidae)
Next Article in Special Issue
Genetic Mechanisms of Asthma and the Implications for Drug Repositioning
Previous Article in Journal
Genome-Guided Analysis of Clostridium ultunense and Comparative Genomics Reveal Different Strategies for Acetate Oxidation and Energy Conservation in Syntrophic Acetate-Oxidising Bacteria
Previous Article in Special Issue
Transgenic Xenopus laevis Line for In Vivo Labeling of Nephrons within the Kidney
Open AccessArticle

BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients

1
Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland
2
Department of Internal, Occupational Diseases, Hypertension and Clinical Oncology, Wroclaw Medical University, 50-556 Wrocław, Poland
*
Author to whom correspondence should be addressed.
Genes 2018, 9(5), 226; https://doi.org/10.3390/genes9050226
Received: 27 February 2018 / Revised: 16 April 2018 / Accepted: 17 April 2018 / Published: 24 April 2018
(This article belongs to the Special Issue DNA Variations in Evolution and Human Diseases)
Multiple myeloma (MM) is a haematologic malignancy characterized by the presence of atypical plasma cells. Basigin (BSG, CD147) controls lactate export through the monocarboxylic acid transporter 1 (MCT1, SLC16A1) and supports MM survival and proliferation. Additionally, BSG is implicated in response to treatment with immunomodulatory drugs (thalidomide and its derivatives). We investigated the role of single nucleotide polymorphisms (SNPs) in the gene coding for BSG and SLC16A1 in MM. Following an in silico analysis, eight SNPs (four in BSG and four in SLC16A1) predicted to have a functional effect were selected and analyzed in 135 MM patients and 135 healthy individuals. Alleles rs4919859 C, rs8637 G, and haplotype CG were associated with worse progression-free survival (p = 0.006, p = 0.017, p = 0.002, respectively), while rs7556664 A, rs7169 T and rs1049434 A (all in linkage disequilibrium (LD), r2 > 0.98) were associated with better overall survival (p = 0.021). Similar relationships were observed in thalidomide-treated patients. Moreover, rs4919859 C, rs8637 G, rs8259 A and the CG haplotype were more common in patients in stages II–III of the International Staging System (p < 0.05), while rs8259 A correlated with higher levels of β-2-microglobulin and creatinine (p < 0.05). Taken together, our results show that BSG and SLC16A1 variants affect survival, and may play an important role in MM. View Full-Text
Keywords: basigin; monocarboxylic acid transporter 1; single nucleotide polymorphisms; multiple myeloma; survival basigin; monocarboxylic acid transporter 1; single nucleotide polymorphisms; multiple myeloma; survival
Show Figures

Figure 1

MDPI and ACS Style

Łacina, P.; Butrym, A.; Mazur, G.; Bogunia-Kubik, K. BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients. Genes 2018, 9, 226.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop